Boston, MA, April 16, 2025 – Cytodigm, a leader in advanced nanoparticle delivery systems, in collaboration with Harvard Medical School and Brown University, proudly announces the publication of groundbreaking research in the Feb 2025 issue of Science Advances. The study, titled “Modulation of Blood-Tumor Barrier Transcriptional Programs Improves Intratumoral Drug Delivery and Potentiates Chemotherapy in GBM,” showcases the innovative potential of Cytodigm’s proprietary nanoparticle, PPRX-1701, in overcoming delivery challenges associated with glioblastoma multiforme (GBM).
The research addresses a significant challenge in treating GBM: efficient drug delivery, which is hindered by the blood-brain barrier (BBB) and the blood-tumor barrier (BTB). These barriers prevent most chemotherapies from effectively reaching the brain. Researchers identified a 12-gene transcriptional signature associated with the BTB in GBM, with CDH5 identified as a key molecule, confirmed through transcriptomics and immunostaining of patient specimens.
PPRX-1701 utilizes Cytodigm’s cutting-edge technology to encapsulate indirubin, a naturally occurring anti-tumor agent, and its derivative, 6-bromoindirubin acetoxime (BIA). BIA targets these barriers by down-regulating CDH5 and associated BTB signature genes, facilitating endothelial barrier disruption in vitro and murine GBM xenograft models. Treatment with BIA increased the accumulation of cisplatin within tumors and enhanced DNA damage by targeting DNA repair pathways. By using an injectable formulation of BIA within PPRX-1701, the efficacy of cisplatin was significantly improved in murine GBM models.
“We are thrilled to co-author this pivotal research with Harvard and Brown, demonstrating PPRX-1701’s potential to redefine GBM treatment by effectively delivering and enhancing chemotherapy efficacy,” said Bin Wu, Founder and CEO of Cytodigm. “This work highlights our commitment to advancing innovative solutions that address critical medical needs.”
For more information, please contact: info@cytodigm.com.
About Cytodigm:
Cytodigm is a biopharmaceutical company committed to developing transformative therapeutic delivery platforms targeting complex diseases. Collaborating with esteemed academic and research institutions, Cytodigm is dedicated to bringing cutting-edge therapies to patients globally.
